atogepant (Qulipta)
Jump to navigation
Jump to search
Indications
Contraindications
- renal insufficiency, hepatic insufficiency, pregnancy, lactation may be issues
Dosage
- once-daily oral dose of 10 mg, 30 mg, or 60 mg
* atogepant 30 mg twice a day & 60 mg once a day reduce mean monthly migraine days
* 1.5-1.7 fewer migraine days per month than with placebo
* placebo effect less than, but > 1/2 the effect of atogepant
* see clinical trials below
Adverse effects
- constipation 7-10%
- nausea 4-6%
- fatigue
Mechanism of action
Clinical trials
- PROGRESS trial
- ELEVATE trial
More general terms
References
- ↑ George J Novel Migraine Prevention Drug Wins FDA Nod. Atogepant approval reflects "broader shift" in managing migraine. MedPage Today September 29, 2021 https://www.medpagetoday.com/neurology/migraines/94759
- ↑ Greb E FDA Okays New Oral CGRP Antagonist for Migraine Prevention. Medscape. September 29, 2021 https://www.medscape.com/viewarticle/959919
- ↑ 3.0 3.1 Pozo-Rosich P, Ailani J, Ashina M, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Jul 26:S0140-6736(23)01049-8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37516125 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01049-8/fulltext
- ↑ 4.0 4.1 Tassorelli C, Nagy K, Pozo-Rosich P, et al. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol. 2024 Feb 13:S1474-4422(24)00025-5 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38364831
- ↑ 5.0 5.1 Goadsby PJ, Friedman DI, Holle-Lee D, et al. Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial. Neurology. 2024 Jul 23;103(2):e209584. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38924724 PMCID: PMC11254449